Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …
To evaluate the therapeutic effects of Tripterygium wilfordii glycosides on endometriosis (EMs) and their effects on serum sex hormone levels, tumour markers, and inflammatory factors (serum CA125, CA199, Estradiol, FSH, …
Current interventions for endometriosis mainly involve hormone therapies but have limited efficacy and unacceptable side effects due to the lack of selectivity to distinguish between endometriosis and endometrial tissues. Elucidating …
IntroductionTransgender men are assigned female sex at birth, but identify with a masculine gender identity, prompting them to undergo gender-affirming surgery, usually following androgen therapy, which induces changes in histology …
Medical therapy is crucial in the long-term management of endometriosis, and its clinical efficacy must be balanced with a favorable safety profile.
The microbiota constitutes a vital component of the human microenvironment, dynamically responding to physiological changes and playing crucial roles in maintaining normal bodily functions. Endometriosis (EMs), defined as a chronic, …
Endometriosis contributes to 5-21% of hospital admissions for pelvic pain. While hormonal therapies are pivotal in managing endometriosis-related pain, no single hormonal treatment suits all patients. We aimed to assess …
Ovarian stimulation is used in assisted reproductive technology to help infertile couples achieve pregnancy. Luteal-phase stimulation with progestin-primed ovarian stimulation (PPOS) is a practical approach, as it involves oral medication …
In recent years, there has been a surge of interest in alternative and natural techniques for preventing and treating gynecological disorders. Numerous studies have focused on exploring treatments that have …
To evaluate the progression of endometriosis and painful symptoms in young women (≤ 25 years) with severe dysmenorrhea (Visual Analogue Scale score ≥ 7), with or without ultrasound-detected endometriosis, over …